Glaukos (NYSE:GKOS) Stock: Insider Joseph Gilliam Sells 861 Shares

Glaukos Corporation (NYSE:GKOS – Get Free Report) COO Joseph Gilliam sold 861 shares of the stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $250.00, for a total value of $215,250.00. Following the completion of the sale, the chief operating officer directly owned 71,602 shares of the company’s stock, valued at $17,900,500. This represents a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Glaukos Trading Up 2.2%

Shares of Glaukos stock opened at $238.17 on Friday. The company’s fifty day simple moving average is $189.52 and its 200-day simple moving average is $149.49. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.09 and a current ratio of 4.57. Glaukos Corporation has a 1 year low of $93.78 and a 1 year high of $255.18.

Glaukos (NYSE:GKOS – Get Free Report) last released its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.57. The firm had revenue of $211.03 million during the quarter, compared to analysts’ expectations of $168.04 million. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The business’s quarterly revenue was up 58.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.16) EPS. As a group, sell-side analysts expect that Glaukos Corporation will post 0.50 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Glaukos

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GKOS. Kestra Advisory Services LLC acquired a new position in shares of Glaukos in the 3rd quarter worth approximately $200,000. EWA LLC bought a new stake in Glaukos during the 3rd quarter worth approximately $218,000. Algert Global LLC grew its position in Glaukos by 43.7% during the 3rd quarter. Algert Global LLC now owns 44,361 shares of the medical instruments supplier’s stock worth $7,284,000 after acquiring an additional 13,490 shares during the last quarter. Castleark Management LLC acquired a new stake in Glaukos during the 3rd quarter valued at $7,812,000. Finally, Virtu Financial LLC acquired a new stake in Glaukos during the 3rd quarter valued at $338,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on GKOS shares. Stifel Nicolaus upped their price objective on shares of Glaukos from $190.00 to $225.00 and gave the company a “buy” rating in a research report on Thursday, October 29th. Needham & Company LLC lifted their target price on Glaukos from $201.00 to $251.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. JPMorgan Chase & Co. boosted their price target on Glaukos from $200.00 to $240.00 and gave the company an “overweight” rating in a research note on Thursday, October 29th. Piper Sandler restated an “overweight” rating and set a $240.00 price target (up from $195.00) on shares of Glaukos in a research note on Thursday, October 29th. Finally, Zacks Research raised Glaukos from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 28th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Glaukos has a consensus rating of “Moderate Buy” and a consensus target price of $218.00.

Check Out Our Latest Report on Glaukos

Key Stories Impacting Glaukos

These are some of the GKOS stories that stood out recently:

  • Positive Sentiment: Zacks Research raised its Q1 2028 EPS estimate to $0.27 from $0.18 and its Q2 2028 estimate to $0.45 from $0.37, while maintaining a “Strong Buy” rating. Higher forecasts may reinforce expectations for continued earnings growth.
  • Positive Sentiment: A recent report attributed Glaukos’ 48.2% rally since the end of September to strong third-quarter results, increased sales guidance, growth in Epioxa and iDose TR, and positive clinical data. What Drove Glaukos Stock’s 48% Rally Since the End of September?
  • Negative Sentiment: COO Joseph Gilliam sold 861 shares for $215,250. The sale reduced his holdings by 1.19%; he still owned 71,602 shares afterward, making the transaction relatively small compared with his remaining stake. Glaukos Insider Sale

About Glaukos

(Get Free Report)

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.

Featured Articles

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.